-
Sarepta Therapeutics Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
NASDAQ: $SRPT Sarepta Therapeutics (NasdaqGS: $SRPT) is at the forefront of innovation in the treatment of Duchenne Muscular Dystrophy (DMD) with its groundbreaking gene therapy, ELEVIDYS. As a rare, progressive genetic disorder, DMD significantly impairs muscle function and can lead to severe health complications. In an effort to provide new hope to affected individuals and…